185 related articles for article (PubMed ID: 32750197)
21. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors.
Steininger PA; Strasser EF; Weiss D; Achenbach S; Zimmermann R; Eckstein R
Vox Sang; 2014 Apr; 106(3):248-55. PubMed ID: 24152115
[TBL] [Abstract][Full Text] [Related]
22. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
24. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience.
Burstein DS; Maude S; Grupp S; Griffis H; Rossano J; Lin K
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1590-1595. PubMed ID: 29772353
[TBL] [Abstract][Full Text] [Related]
25. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
26. Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
Allen ES; Stroncek DF; Ren J; Eder AF; West KA; Fry TJ; Lee DW; Mackall CL; Conry-Cantilena C
Transfusion; 2017 May; 57(5):1133-1141. PubMed ID: 28236305
[TBL] [Abstract][Full Text] [Related]
27. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
28. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
[TBL] [Abstract][Full Text] [Related]
29. Collection efficiency and safety of large-volume leukapheresis for the manufacturing of tisagenlecleucel.
Kitamura W; Urata T; Fujii K; Fukumi T; Ikeuchi K; Seike K; Fujiwara H; Asada N; Ennishi D; Matsuoka KI; Otsuka F; Maeda Y; Fujii N
Transfusion; 2024 Apr; 64(4):674-684. PubMed ID: 38419458
[TBL] [Abstract][Full Text] [Related]
30. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
32. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
33. Pediatric apheresis with a novel apheresis device with electronic interface control.
Sörensen J; Jarisch A; Smorta C; Köhl U; Bader P; Seifried E; Bönig H
Transfusion; 2013 Apr; 53(4):761-5. PubMed ID: 22882156
[TBL] [Abstract][Full Text] [Related]
34. What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR-T therapy.
Annen K; Zubair A; Schwartz E; Schwartz J; Szczepiorkowski ZM
J Clin Apher; 2020 Jun; 35(3):234-235. PubMed ID: 32186782
[No Abstract] [Full Text] [Related]
35. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
36. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T cells for acute lymphoblastic leukemia.
Frey NV
Am J Hematol; 2019 May; 94(S1):S24-S27. PubMed ID: 30784101
[TBL] [Abstract][Full Text] [Related]
38. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies.
Thibodeaux SR; Aqui NA; Park YA; Schneiderman J; Su LL; Winters JL; Zubair AC; Schwartz J; Liu HD;
J Clin Apher; 2022 Jun; 37(3):223-236. PubMed ID: 35085413
[TBL] [Abstract][Full Text] [Related]
39. Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high-risk leukemia.
Even-Or E; Di Mola M; Ali M; Courtney S; McDougall E; Alexander S; Schechter T; Whitlock JA; Licht C; Krueger J
Transfusion; 2017 Jun; 57(6):1536-1542. PubMed ID: 28439898
[TBL] [Abstract][Full Text] [Related]
40. Evolution of MNC and lymphocyte collection settings employing different Spectra Optia
Punzel M; Kozlova A; Quade A; Schmidt AH; Smith R
Vox Sang; 2017 Aug; 112(6):586-594. PubMed ID: 28809049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
